60 Degrees Pharmaceuticals (SXTPW) furnishes updated investor presentation

Rhea-AI Filing Summary

60 Degrees Pharmaceuticals, Inc. filed a current report to share that its Chief Executive Officer, Geoffrey Dow, is scheduled to provide investor information beginning on September 9, 2025. The company prepared an investor presentation for this event, which is included as Exhibit 99.1 to the report.

The materials in the presentation are stated to be current as of September 9, 2025, and the company notes it does not undertake to update this information in the future. The presentation is furnished under Regulation FD, meaning it is provided for informational purposes and is not treated as filed for liability purposes under certain securities laws.

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

false 0001946563 DC 0001946563 2025-09-09 2025-09-09 0001946563 SXTP:CommonStockParValue0.0001PerShareMember 2025-09-09 2025-09-09 0001946563 SXTP:WarrantsEachWarrantToPurchaseOneShareOfCommonStockMember 2025-09-09 2025-09-09 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): September 9, 2025

60 DEGREES PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-41719		45-2406880
(State or other jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification Number)

1025 Connecticut Avenue NW Suite 1000, Washington, D.C.		20036
(Address of registrant’s principal executive office)		(Zip code)

(202) 327-5422

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		SXTP		The Nasdaq Stock Market LLC
Warrants, each warrant to purchase one share of Common Stock		SXTPW		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure

Chief Executive Officer, Geoff Dow, of the Company, is scheduled to provide certain investor information, commencing on September 9, 2025. The slide package prepared by the Company for use in connection with this presentation is furnished herewith as Exhibit 99.1. All of the information in the attached presentation is presented as of September 9, 2025, and the Company does not assume any obligation to update such information in the future.

The information included in this Form 8-K, as well as the exhibit referenced herein, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.

Item 9.01 Financial Statements and Exhibits

(a) Exhibits

Number		Description
99.1		Company Investor Presentation, dated as of September 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	60 DEGREES PHARMACEUTICALS, INC.
Date: September 9, 2025	By:	/s/ Geoffrey Dow
	Name:	Geoffrey Dow
	Title:	Chief Executive Officer and President

2

FAQ

What is 60 Degrees Pharmaceuticals, Inc. (SXTPW) disclosing in this 8-K?

The company is disclosing that its CEO, Geoffrey Dow, will provide investor information starting on September 9, 2025, using an investor presentation furnished as Exhibit 99.1.

What is included as Exhibit 99.1 for 60 Degrees Pharmaceuticals (SXTPW)?

Exhibit 99.1 is a Company Investor Presentation dated as of September 2025, prepared for use in investor meetings beginning on September 9, 2025.

Is the investor presentation for SXTPW considered filed with the SEC?

No. The investor presentation is furnished under Regulation FD and is explicitly stated not to be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 or incorporated by reference into Securities Act filings.

As of what date is the information in the SXTPW investor presentation current?

All information in the investor presentation is presented as of September 9, 2025, and the company states it does not assume any obligation to update it.

Who signed the 8-K for 60 Degrees Pharmaceuticals (SXTPW)?

The report was signed on behalf of 60 Degrees Pharmaceuticals, Inc. by Geoffrey Dow, who is the Chief Executive Officer and President.

On which exchange are 60 Degrees Pharmaceuticals’ common stock and warrants listed?

The company’s common stock trades on The Nasdaq Stock Market LLC under the symbol SXTP, and its warrants trade on Nasdaq under the symbol SXTPW.